An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia

Modern Rheumatology

Volumn 27, Issue 4, 2017, Pages 688-695

  Murakami, Masato ^a   Osada, Kenichi ^b   Ichibayashi, Hisao ^c   Mizuno, Hiromichi ^c   Ochiai, Toshimitsu ^c   Ishida, Mitsuhiro ^c   Alev, Levent ^d   Nishioka, Kusuki ^e  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

^d ELI LILLY AND COMPANY   (United States)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Duloxetine; Fibromyalgia; Japan; Long term safety; Open label

Indexed keywords

ALANINE AMINOTRANSFERASE; DULOXETINE; GAMMA GLUTAMYLTRANSFERASE; ANALGESIC AGENT;

ADULT; ALLERGY; ARTICLE; BACKACHE; BRIEF PAIN INVENTORY; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; FOLLOW UP; HEADACHE; HUMAN; INCIDENCE; INSOMNIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALAISE; MALE; MIDDLE AGED; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SOMNOLENCE; THIRST; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; VERTIGO; WEIGHT GAIN; BODY WEIGHT GAIN; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; TREATMENT OUTCOME;

ADULT; ANALGESICS; CONSTIPATION; DULOXETINE HYDROCHLORIDE; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; NAUSEA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84992697267     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2016.1245237     Document Type: Article

References (28)

1. Japan College of Fibromyalgia Investigation, ed. Guidelines for diagnosis and treatment of fibromyalgia 2013. Japan:Japan Medical Journal Co. Ltd; 2013.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72.
3. Wolfe F, Ross K, Anderson J, Russell I, Hebert L., The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28.
4. Clauw DJ, ed. Fibromyalgia–the evolution of new treatment strategies for improving patient care. Am J Med. 2009;122(12)(Suppl. A):S1–S58.
5. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L., An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
6. Nakamura I, Nishioka K, Usui C, Osada K, Ichibayashi H, Ishida M, et al. An epidemiologic internet survey of fibromyalgia and chronic pain in Japan. Arthritis Care Res. 2014; 66:1093–101.
7. Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, et al. Determinants of health status in fibromyalgia:a comparative study with systemic lupus erythematosus. J Rheumatol. 2000;27:365–72.
8. Matsumoto Y, Maeda S, Tamakoshi A, Nishioka K., A nationwide epidemiological survey for patients with fibromyalgia in Japan. [In Japanese]. Clin Rheumatol. 2006;18:87–92.
9. Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, et al. Efficacy of duloxetine in patients with fibromyalgia:pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry. 2009;11:237–44.
10. Choy EH, Mease PJ, Kajdasz DK, Wohlreich MM, Crits-Christoph P, Walker DJ, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia:pooled analysis of data from five clinical trials. Clin Rheumatol. 2009;28:1035–44.
11. Murakami M, Osada K, Mizuno H, Ochiai T, Alev L, Nishioka K., A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients. Arthritis Res Ther. 2015;17:224.
12. Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D’Souza DN, Moldofsky H., A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009;25:365–75.
13. Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39:454–64.
14. Yasuda H, Hotta N, Kasuga M, Kashigawi A, Kawamori R, Yamada T, et al. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain:results from a randomized, 52-week, open-label study. J Diabetes Investig. 2016;7:100–8.
15. Cleeland CS, Ryan KM., Pain assessment:global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–38.
16. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese:the utility of the Japanese Brief Pain Inventory-BPI-J. J Pain Symptom Manage 1998;16:364–73.
17. Hata T, Kita T, Itoh E, Oyama R, and Kawabata A., Mechanism of the analgesic effect of neurotropin. Jpn J Pharmacol. 1988;48:165–73.
18. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale:initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–77.
19. Guy W., ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Rockville, MD:US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
20. Osada K, Oka H, Isomura T, Nakamura I, Tominaga K, Takahashi S, et al. Development of the Japanese version of the Fibromyalgia Impact Questionnaire (JFIQ):psychometric assessments of reliability and validity. Int J Rheum Dis. 2011;14:74–80.
21. Burckhardt CS, Clark SR, Bennett RM., The Fibromyalgia Impact Questionnaire:development and validation. J Rheumatol. 1991;18:728–33.
22. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K., Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol. 1998;51:1037–44.
23. Fukuhara S, Ware JE, Kosinski M, Wada S, and Gandek B., Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol. 1998;51:1045–53.
24. Beck AT, Steer RA, Brown GK., Manual for the Beck Depression Inventory-2. San Antonio, TX:Psychological Corporation; 1996.
25. Kojima M, Furukawa TA, Takahashi H, Kawai M, Nagaya T, Tokudome S., Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res. 2002;110:291–9.
26. Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, et al. The Japanese version of the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale:reliability and validity. Mod Rheumatol. 2012;22:40–4.
27. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–10.
28. Higuchi T., Clinical evaluation of duloxetine in the treatment of major depressive disorder—long-term treatment study in major depressive disorder. Jpn J Clin Psychopharmacol. 2009;12:1579–93.